{"url_path":"/sec/vani/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1266806/0001753926-26-001109-index.html","accession_number":"0001753926-26-001109","cik":"0001266806","ticker":"VANI","issuer_name":"Vivani Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1266806/0001753926-26-001109-index.html","primary_entity_key":"0001266806","primary_entity_name":"Vivani Medical, Inc."},"word_count":67,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\n \n\nOn June 25, 2026, Vivani announced that it received regulatory approval from Bellberry, a human research ethics committee in Australia to initiate SLIM-1™, a Phase 1 clinical trial of NPM-139, a semaglutide implant. A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference."}